High-dose chemotherapy or chemoradiation therapy supported with autologous stem cell transplantation is now recognized as a valid therapeutic option for patients with multiple myeloma. Results of randomized trials have established autografting as the treatment of choice for patients younger than 65 years, as part of their initial therapy. In this review, the issues of who benefits from transplant, what is the optimal procedure, and whether there is a potential role for allografting are addressed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
stem cell
8
cell transplantation
8
multiple myeloma
8
transplantation multiple
4
myeloma current
4
current status
4
status future
4
future directions
4
directions high-dose
4
high-dose chemotherapy
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!